Peter Kaufman, MD
Medical Oncology · Lebanon, NHNPI 1336151141
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. Lilly USA, LLC accounts for 71.4% of it on its own, with 27 other manufacturers making up the rest. Among medical oncology clinicians in NH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 802 payments — averaging $811.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$465K
- AstraZeneca$48K
- Eli Lilly$38K
- Seagen Inc.$30K
- Eisai Inc.$21K
- Bristol Myers Squibb$9K
- plus $41K from 22 others
Across 251 payments — averaging $8941.66 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$2M
- Pfizer$120K
- Eisai Inc.$53K
- Sanofi US Services Inc.$41K
- Sanofi$3K
- F. Hoffmann-la Roche AG$824
- plus $475 from 2 others
What the payments were for
- Consulting fees$180,28228%
- Speaking & faculty fees$352,78554%
- Grants$2500%
- Travel & lodging$105,87016%
- Food & beverage$11,5462%
- Education$570%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 636 | $464,668 |
| AstraZeneca | 34 | $47,650 |
| Eli Lilly | 63 | $37,704 |
| Seagen Inc. | 10 | $29,696 |
| Eisai Inc. | 10 | $21,224 |
| Bristol Myers Squibb | 7 | $8,713 |
| Eisai CO., LTD. | 2 | $6,024 |
| Ipsen Bioscience Inc. | 7 | $5,857 |
| Sanofi | 2 | $5,103 |
| F. Hoffmann-la Roche AG | 3 | $5,035 |
| Daiichi Sankyo Inc. | 7 | $4,170 |
| Teva Pharmaceuticals USA, Inc. | 2 | $3,521 |
| Genentech USA, Inc. | 1 | $2,280 |
| Immunomedics, Inc. | 1 | $2,100 |
| Pfizer | 1 | $1,900 |
| Macrogenics, Inc. | 1 | $1,500 |
| Merck | 1 | $1,074 |
| Dr.reddy's Laboratories,inc. | 1 | $1,000 |
| Athenex Pharmaceutical Division, LLC | 2 | $522 |
| Institut DE Recherches Internationales Servier | 2 | $372 |
| Genentech, Inc. | 1 | $149 |
| Astrazeneca UK Limited | 1 | $135 |
| Veru Inc. | 1 | $129 |
| Jazz Pharmaceuticals Inc. | 1 | $95 |
| Puma Biotechnology, Inc. | 1 | $70 |
| TELA Bio, Inc. | 1 | $50 |
| E.r. Squibb & Sons, L.L.C. | 2 | $37 |
| Gilead | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$650,788 in reported general payments places this provider in the 95th percentile of 20 medical oncology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 14 | $208,302 |
| IbrancePalbociclib | 11 | $172,568 |
| Everolimus | 11 | $19,030 |
| Toremifene Citrate | 11 | $13,034 |
| Letrozole | 207 | $6,066 |
| Exemestane | 14 | $2,980 |
| Enoxaparin Sodium | 12 | $1,278 |
| Anastrozole | 43 | $1,050 |
| Tamoxifen Citrate | 21 | $525 |
| Ondansetron OdtOndansetron | 13 | $74 |
| Citalopram HbrCitalopram Hydrobromide | 11 | $34 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCVerzenio | $464,668 | $208,30214 claims |
| PfizerIbrance | $1,900 | $172,56811 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 20 medical oncology providers in New Hampshire.
Other medical oncology in Lebanon
- James RigasLebanon$251K
- Tyler CurielLebanon$29K
- Charles GaulinLebanon$20K
- Linda VahdatLebanon$20K
- Tara KaufmannLebanon$656
- Hilal HachemLebanon$368
- Jacob ReibelLebanon$87
- Mary ChamberlinLebanon$70
- Gabriel BrooksLebanon$50
- Bradley ArrickLebanon$12
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.